Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Erkko Ylösmäki; Leena Ylösmäki; Manlio Fusciello; Beatriz Martins; Petra Ahokas; Hanne Cojoc; Arttu Uoti; Sara Feola; Anna Kreutzman; Tuuli Ranki; Julia Karbach; Tapani Viitala; Petri Priha; Elke Jäger; Sari Pesonen; Vincenzo Cerullo

doi:10.1016/j.omto.2021.02.006

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen, Vincenzo Cerullo

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Molecular Therapy - Oncolytics
Volume	20
Pages (from-to)	459-469
Number of pages	11
ISSN	2372-7705
DOIs	https://doi.org/10.1016/j.omto.2021.02.006
Publication status	Published - 26 Mar 2021
MoE publication type	A1 Journal article-refereed

Fields of Science

317 Pharmacy
3122 Cancers

Access to Document

10.1016/j.omto.2021.02.006

1-s2.0-S2372770521000243-mainFinal published version, 1.58 MBLicence: CC BY

Cite this

Ylösmäki, E., Ylösmäki, L., Fusciello, M., Martins, B., Ahokas, P., Cojoc, H., Uoti, A., Feola, S., Kreutzman, A., Ranki, T., Karbach, J., Viitala, T., Priha, P., Jäger, E., Pesonen, S., & Cerullo, V. (2021). Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Molecular Therapy - Oncolytics, 20, 459-469. https://doi.org/10.1016/j.omto.2021.02.006

@article{932e2a74e5334a4bb519c411f9be1ebf,

title = "Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform",

keywords = "317 Pharmacy, 3122 Cancers",

author = "Erkko Yl{\"o}sm{\"a}ki and Leena Yl{\"o}sm{\"a}ki and Manlio Fusciello and Beatriz Martins and Petra Ahokas and Hanne Cojoc and Arttu Uoti and Sara Feola and Anna Kreutzman and Tuuli Ranki and Julia Karbach and Tapani Viitala and Petri Priha and Elke J{\"a}ger and Sari Pesonen and Vincenzo Cerullo",

year = "2021",

month = mar,

day = "26",

doi = "10.1016/j.omto.2021.02.006",

language = "English",

volume = "20",

pages = "459--469",

journal = "Molecular Therapy - Oncolytics",

issn = "2372-7705",

publisher = "Cell Press",

}

Ylösmäki, E, Ylösmäki, L, Fusciello, M, Martins, B, Ahokas, P, Cojoc, H, Uoti, A, Feola, S , Kreutzman, A, Ranki, T, Karbach, J, Viitala, T, Priha, P, Jäger, E, Pesonen, S & Cerullo, V 2021, 'Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform', Molecular Therapy - Oncolytics, vol. 20, pp. 459-469. https://doi.org/10.1016/j.omto.2021.02.006

TY - JOUR

T1 - Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

AU - Ylösmäki, Erkko

AU - Ylösmäki, Leena

AU - Fusciello, Manlio

AU - Martins, Beatriz

AU - Ahokas, Petra

AU - Cojoc, Hanne

AU - Uoti, Arttu

AU - Feola, Sara

AU - Kreutzman, Anna

AU - Ranki, Tuuli

AU - Karbach, Julia

AU - Viitala, Tapani

AU - Priha, Petri

AU - Jäger, Elke

AU - Pesonen, Sari

AU - Cerullo, Vincenzo

PY - 2021/3/26

Y1 - 2021/3/26

KW - 317 Pharmacy

KW - 3122 Cancers

U2 - 10.1016/j.omto.2021.02.006

DO - 10.1016/j.omto.2021.02.006

M3 - Article

SN - 2372-7705

VL - 20

SP - 459

EP - 469

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

ER -